Clinical Trial Update: Rituximab Plus Lenalidomide in Patients With Mucosa Associated Lymphoid Tissue [Phase 2]

View source ↗

Summary

Phase 2 trial results for rituximab plus lenalidomide in mucosa-associated lymphoid tissue lymphoma (MALT lymphoma) have been reported.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mucosa-associated Lymphoid Tissue Lymphoma

Drugs mentioned

• Lenalidomide (lenalidomide)
• Rituximab (rituximab)

Snippet

Sponsor: Arbeitsgemeinschaft medikamentoese Tumortherapie | Conditions: Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) | Phase 2 | Status: COMPLETED | Results posted: 2017-11-06